Retatrutide vs Tirzepatide: trials and field reports

Key takeaways

• Three receptors versus two. Retatrutide activates GIP, GLP-1, and glucagon. Tirzepatide activates GIP and GLP-1. The third receptor is what people credit for the bigger weight signal and the bigger heart-rate and energy-expenditure shifts on reta .
• Top trial doses, cross-trial read: Phase 2 reta 12 mg ran about 24.2 percent at 48 weeks (n=338). TRIUMPH-4 Phase 3 reta 12 mg ran about 28.7 percent on the efficacy estimand at 68 weeks (n=445; Lilly topline figure, not yet peer-reviewed). SURMOUNT-1 tirz 15 mg ran about 20.9 percent at 72 weeks (n=2,539). Different populations, different durations, no head-to-head .
• GI burden at top dose: about 45 percent of reta 12 mg participants reported at least one nausea event over 48 weeks versus about 29 percent of tirz 15 mg participants over 72 weeks. Vomiting on reta 12 mg ran roughly twice the tirz 15 mg rate; constipation tracked in a similar low-to-mid-teens range (reta 12 mg about 16 percent, tirz 15 mg about 12 percent) .
• New signal at higher reta doses: TRIUMPH-4 reported dysesthesia (altered touch sensation) in about 8.8 percent at 9 mg and about 20.9 percent at 12 mg versus 0.7 percent on placebo. Not on the tirzepatide label as a common adverse event .
• Regulatory status: tirzepatide is FDA-approved as Mounjaro (2022) and Zepbound (2023). Retatrutide has no approved label, no approved dose, and is not on the FDA bulk substances list for traditional 503A compounding. Everything sold as retatrutide outside the TRIUMPH program is gray-market of unverifiable identity, purity, and concentration .

Skip to:

• At a glance: reta vs tirz
• What we are actually comparing
• Onset and the first four weeks: appetite, food noise, and the scale
• GI tolerability: nausea, vomiting, diarrhea, constipation
• Heart rate, body heat, and the glucagon arm
• Weight trajectory week by week
• The dysesthesia signal and other new findings
• Cardiometabolic markers and what people track at home
• Titration patterns and how users compare them
• Mood, sleep, energy, and quality of life
• The gray-market caveat (this is the load-bearing one)
• What still needs to read out
• Bottom line

At a glance: reta vs tirz

The question most readers actually came for is whether reta or tirz wins on the dimensions they care about. Here is the side-by-side across the eight dimensions where trial data exists for both drugs. There is no head-to-head trial, so every line below is a cross-trial read. Treat it as orientation, not as a precise effect-size estimate.

• Top studied weekly dose. Retatrutide: 12 mg in Phase 2 and TRIUMPH-4 (a 9 mg arm also in Phase 3). Tirzepatide: 15 mg on the SURMOUNT and SURPASS labels .
• Receptor profile. Reta: GIP, GLP-1, glucagon (triple agonist). Tirz: GIP and GLP-1 (dual agonist) .
• Top weight loss in obesity. Reta 12 mg: about 24.2 percent at 48 weeks (Phase 2) and about 28.7 percent on the efficacy estimand at 68 weeks (TRIUMPH-4). Tirz 15 mg: about 20.9 percent at 72 weeks (SURMOUNT-1) .
• Resting heart rate at top dose. Reta 12 mg: about 6 to 7 bpm over baseline in Phase 2. Tirz 15 mg: about 2 to 4 bpm over baseline in SURMOUNT-1 .
• Nausea incidence at top dose. Reta 12 mg: about 45 percent reporting at least one event over 48 weeks. Tirz 15 mg: about 29 percent over 72 weeks .
• Distinctive new safety signal. Reta: dysesthesia at 9 and 12 mg in TRIUMPH-4 (8.8 percent and 20.9 percent versus 0.7 percent on placebo). Tirz: nothing comparable on the current label .
• Systolic blood pressure drop at top dose. Reta 12 mg: about 14.0 mm Hg at 68 weeks (TRIUMPH-4). Tirz 15 mg: about 7.2 mm Hg at 72 weeks (SURMOUNT-1) .
• Regulatory status as of mid-2026. Reta: investigational, no approved label, no FDA bulk-substance status, full TRIUMPH program still reading out. Tirz: FDA-approved as Mounjaro (T2D, 2022) and Zepbound (chronic weight management, 2023), with SURMOUNT-OSA adding sleep apnea .

What we are actually comparing

Tirzepatide is the dual GLP-1 / GIP receptor agonist already on the US label as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). It is a once-weekly subcutaneous injection titrated stepwise from 2.5 mg up to 15 mg. Its prescribing information is on DailyMed .

Retatrutide is Eli Lilly's investigational once-weekly subcutaneous triple agonist of the GIP, GLP-1, and glucagon receptors. It is not FDA-approved. The Phase 2 obesity trial used 1, 4, 8, and 12 mg dose arms; Phase 3 (the TRIUMPH program) uses 9 and 12 mg as efficacy doses. The Phase 3 program reads out across obesity, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, knee osteoarthritis, and a dedicated cardiovascular and kidney outcomes trial .

Onset and the first four weeks: appetite, food noise, and the scale

The most consistent thing users report when switching from tirzepatide to retatrutide, or starting reta after a long tirz run, is a sharper drop in appetite in the first 2 to 4 weeks at a comparable dose. The trial-data anchor for that pattern is the Phase 2 weight trajectory: at week 24 (a primary timepoint), retatrutide had already produced larger weight reduction than what tirzepatide produced at the same week in SURMOUNT-1, before either curve had finished its first-half decline .

Community-aggregated experience reports (self-reported and not peer-reviewed) most commonly describe the first reta dose as producing a quieter or 'flatter' food drive within 36 to 72 hours of the first injection, compared to a slower ramp on tirzepatide. People who track 'food noise' (the intrusive thinking-about-food rumination that many users report subsides on incretin therapy) commonly say the effect is faster and more pronounced on reta, though it is also more likely to overshoot into total disinterest in food in the first week or two. Treat that pattern as a useful signal from a weaker source, not as a trial-grade finding.

Scale movement in the first month on reta typically tracks the Phase 2 weight curve: roughly 2 to 5 percent body weight reduction by week 4 at active doses, comparable to tirzepatide week 8 to 12 numbers from SURMOUNT-1. Most of that early loss is fluid plus glycogen, not fat mass; both drugs front-load the scale effect this way and both flatten later in titration .

GI tolerability: nausea, vomiting, diarrhea, constipation

Both drugs share the class-typical GI side effect cluster: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, eructation, and dyspepsia. Most events are mild to moderate and most cluster in the titration period. The DailyMed labels for tirzepatide list these as the most common adverse events at 5 percent or higher incidence in the SURMOUNT and SURPASS trials .

Phase 2 retatrutide GI rates rose with dose. At 12 mg, nausea ran roughly 45 percent, diarrhea roughly 15 percent, vomiting roughly 20 percent, and constipation roughly 16 percent. Treatment discontinuation due to adverse events ranged from about 6 percent at 1 mg to about 16 percent at 12 mg. Phase 3 TRIUMPH-4 reported a similar overall GI pattern with treatment-attributable discontinuation in the single digits at both 9 and 12 mg .

• Phase 2 reta nausea at 12 mg: about 45 percent of participants reported at least one nausea event over 48 weeks .
• SURMOUNT-1 tirz nausea at 15 mg: about 29 percent of participants reported at least one nausea event over 72 weeks .
• Vomiting on reta 12 mg ran roughly twice the rate seen on tirz 15 mg, consistent with the larger glucagon-driven gut motility shift .
• Constipation at top studied dose runs in a similar low-to-mid-teens range: reta 12 mg ran 16 percent (10 of 62) over 48 weeks and tirz 15 mg ran about 12 percent over 72 weeks .

Community-aggregated reports (self-reported, not peer-reviewed) tend to describe lower reta doses (1 to 4 mg) as roughly equivalent to mid-range tirz (5 to 10 mg) for GI burden, with the curve getting noticeably steeper at 8 mg and above. People who tolerated tirz well do not automatically tolerate high-dose reta well. People who never reached the top tirz dose because of GI almost never reach 12 mg reta either.

Heart rate, body heat, and the glucagon arm

The third receptor (glucagon) is what separates reta from tirz at the mechanism level. Glucagon agonism raises hepatic fat oxidation, increases energy expenditure, and raises resting heart rate. Phase 2 reported dose-dependent heart-rate increases consistent with that mechanism; mean increases at the top dose were in the range of 6 to 7 beats per minute over baseline .

Tirzepatide also raises resting heart rate, but the magnitude is smaller (typically 2 to 4 bpm at top dose in SURMOUNT-1) and the underlying mechanism is mostly attributed to GLP-1 receptor signaling and to weight loss itself rather than to a separate energy-expenditure arm .

Community-aggregated reports (self-reported) commonly describe a 'running warmer' effect on reta: more frequent flushing sensations, mild night sweats, and slightly higher resting heart rates on wearables in the first 4 to 8 weeks of titration. People tracking resting heart rate on Apple Watch, Garmin, or Whoop frequently report a sustained 5 to 10 bpm rise at active reta doses, settling somewhat over time. These are wearable signals, not clinic measurements, so treat the magnitude as approximate.

Weight trajectory week by week

The shape of the weight curve is similar on both drugs: steep loss in the first 12 to 16 weeks, slower loss through weeks 16 to 40, then a flatter trajectory that does or does not plateau depending on dose. The difference is the slope and the floor. The deeper physiology of why the curve flattens at all (and what users can and cannot do about it) is covered in GLP-1 plateau physiology.

• SURMOUNT-1 tirzepatide 15 mg reached about 15 percent reduction by week 36 and about 20.9 percent by week 72 .
• Phase 2 reta 12 mg reached about 17 percent by week 24 and about 24.2 percent by week 48; the curve had not visibly plateaued at week 48 .
• TRIUMPH-4 extended the reta 12 mg curve to 68 weeks: about 28.7 percent on the efficacy estimand. The curve still does not look fully flat at 68 weeks at 12 mg, which is part of why TRIUMPH-1 is running 80 weeks .
• On the treatment-policy estimand (which includes participants who discontinued treatment), TRIUMPH-4 reported about 20 to 24 percent at the active arms. That estimand is the more conservative number and the one that most resembles real-world outcomes .

User-reported weight trajectories from community-aggregated reports (self-reported) tend to track the trial curves at lower doses (1 to 4 mg reta, 2.5 to 7.5 mg tirz). At higher reta doses (8 and 12 mg) users frequently report scale movement faster than the average trial participant, which is the expected pattern when the user is also restricting intake more aggressively than the trial protocol required. Trial weight loss numbers assume no concurrent intensive diet or behavioral intervention; users who pair the drug with deliberate protein-forward dieting commonly beat the trial averages.

The dysesthesia signal and other new findings

TRIUMPH-4 surfaced a new adverse event signal that did not appear in Phase 2: dysesthesia, an altered sense of touch in which normal sensations can feel unusual, tingling, prickly, burning, or painful. Reported rates in TRIUMPH-4 were about 8.8 percent at the 9 mg arm and about 20.9 percent at 12 mg, versus 0.7 percent on placebo. Treatment discontinuations attributable to dysesthesia were uncommon, and the sponsor has stated it will be tracked across the rest of the TRIUMPH readouts. These TRIUMPH-4 rates come from Lilly topline disclosures and are not yet peer-reviewed or posted to the trial registry .

Dysesthesia is not on the tirzepatide label as a common adverse event. Whether reta-specific dysesthesia is glucagon-driven at sustained high exposure, or a signal that would appear with any incretin-class drug at high enough exposure, is not yet resolved. The TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, and TRIUMPH-Outcomes readouts will give the larger denominator needed to settle that question .

Community-aggregated reports (self-reported, not peer-reviewed) describe dysesthesia at higher reta doses as transient tingling or skin-temperature distortions, more often at the scalp and extremities, lasting minutes to hours and most pronounced in the first few weeks at a new dose. The pattern is consistent with the TRIUMPH-4 numbers, but the incidence cannot be precisely estimated from self-selected community samples.

Cardiometabolic markers and what people track at home

Both drugs move several surrogate cardiometabolic markers in the same direction. Across the SURMOUNT and TRIUMPH programs, the recurring pattern is: HbA1c down, fasting glucose down, triglycerides down, non-HDL cholesterol down, high-sensitivity C-reactive protein down, blood pressure down. The magnitudes at top studied doses differ.

• Systolic blood pressure: SURMOUNT-1 tirzepatide 15 mg cut systolic blood pressure by about 7.2 mm Hg at 72 weeks; TRIUMPH-4 retatrutide 12 mg cut it by about 14.0 mm Hg at 68 weeks. Both reductions are larger than what is typical for a non-antihypertensive drug .
• Triglycerides: both drugs lower triglycerides substantially at top doses. The reta program reports larger absolute reductions than tirz, consistent with the glucagon-driven hepatic fat oxidation arm .
• Liver fat: a Phase 2 substudy of retatrutide in adults with obesity and MASLD/MASH reported approximately 80 percent or greater relative reduction in liver fat content at higher reta doses, larger than typical tirz reductions in comparable substudies. Liver fat reduction does not by itself prove fibrosis improvement; that needs paired biopsy or imaging endpoint trials .
• Fasting glucose and HbA1c: both drugs lower these substantially in diabetic populations. The dedicated TRIUMPH-2 diabetes readout will be the formal comparison point for reta in type 2 diabetes .
• Cardiovascular outcomes (hard endpoints, not surrogate markers): no completed cardiovascular outcomes trial for retatrutide. TRIUMPH-Outcomes is the dedicated trial; readout is pending .

Titration patterns and how users compare them

Tirzepatide titration on the Zepbound label is a stepwise weekly schedule: 2.5 mg for 4 weeks, then 5 mg for at least 4 weeks, then optional steps to 7.5, 10, 12.5, and 15 mg in 4-week increments based on tolerability and response. The label maintenance doses are 5, 10, or 15 mg, and that labeled step schedule is laid out in the GLP-1 ramp planner .

Retatrutide has no labeled titration because it has no label. Phase 2 used a 4-week step schedule with weekly doses of 2 mg, 4 mg, 8 mg, and 12 mg, with intermediate steps to reduce GI burden. TRIUMPH-4 used 4-week steps of 2, 4, 8, and 12 mg on the way to the 12 mg maintenance arm; the 9 mg arm escalated through 2, 4, 6, and 9 mg .

Community-aggregated reports (self-reported) most commonly describe slower-than-trial titration on reta as the dominant pattern: holding 2 mg or 4 mg for 6 to 8 weeks instead of 4, splitting weekly doses, or skipping the 8 mg step entirely and moving from 4 mg to a personal target dose below 12 mg. Users who try to escalate on the trial schedule frequently describe more GI burden than they had on a comparable tirz schedule. People who switched from tirz to reta commonly say their reta '4 mg' felt about like tirz '10 to 12.5 mg' on appetite and fullness, with sharper warmth and a more abrupt food-noise drop. Treat this as community pattern reporting, not as protocol guidance.

Mood, sleep, energy, and quality of life

Trial-grade quality of life data on retatrutide is still thin. TRIUMPH-4 reported WOMAC pain reductions in the obesity + knee osteoarthritis population and IWQOL-Lite-CT improvements at the active arms versus placebo, consistent with the size of the weight loss . SURMOUNT-1 reported similar IWQOL improvements on tirzepatide proportional to weight reduction .

Community-aggregated reports (self-reported, not peer-reviewed) describe a few patterns that diverge between the two drugs. On reta, users more frequently report higher early-week energy on titration days, more vivid dreams, and lighter sleep in the first 2 to 4 weeks at a new dose. On tirz, users more frequently report a flatter, calmer baseline energy with less dream-vividness change. Both drugs have community reports of improved mood that the users themselves attribute mostly to weight loss and mobility, not to a direct mood-lifting mechanism, and depression scoring in published trials of incretin therapy has not moved consistently in either direction.

Alcohol and food-craving suppression is reported across both drugs and across the wider GLP-1 class. Trial data specifically on retatrutide and alcohol have not been published, but the broader incretin-class signal is consistent enough that craving reduction is one of the most commonly reported subjective effects on both reta and tirz.

The gray-market caveat (this is the load-bearing one)

Tirzepatide as Mounjaro or Zepbound is a pharmaceutical-grade product manufactured under FDA CMC oversight, with batch-level identity, potency, and impurity testing. The trial data discussed above for tirzepatide were generated with that product. Where compounded or research-chemical versions of an on-label drug enter the picture, the deeper read is in compounded GLP-1s vs labeled product.

Retatrutide is not on that footing. There is no FDA-approved retatrutide product. Lilly has not commercialized retatrutide for any indication. Everything sold as 'retatrutide' outside the TRIUMPH program is unverified gray-market product, frequently sold via research-chemical vendors. The TRIUMPH trial data do not transfer to that product because the identity, potency, purity, salt form, and excipient profile cannot be assumed from the trial work. The FDA has separately flagged dosing-error patterns and identity issues with compounded GLP-1 products in general .

Practically, this means community experience reports on 'retatrutide' are reports about whatever the user actually injected, not about the trial drug. Some gray-market preparations almost certainly are real retatrutide; some almost certainly are not; users have no good way to tell which is which from the vial alone. Mass-spectrometry identity testing exists (a small set of independent labs offer it) but is not part of most user workflows. Read community reports with that uncertainty in mind.

What still needs to read out

• TRIUMPH-1 (NCT05929066): retatrutide in adults with obesity or overweight, 80-week treatment period. The trial answers whether the weight curve continues falling past 68 weeks and how the drug performs across a broader obesity population .
• TRIUMPH-2: retatrutide in adults with type 2 diabetes. The trial answers whether the magnitude of weight loss in non-diabetic obesity transfers to diabetic obesity (historically smaller in this class) .
• TRIUMPH-3: retatrutide in Class II or III obesity with established cardiovascular disease. The trial answers whether higher-BMI, higher-risk populations gain a similar benefit .
• TRIUMPH-Outcomes (NCT06383390): the dedicated cardiovascular and kidney hard-outcomes trial. The trial answers whether the surrogate-marker shifts translate into reductions in heart attacks, strokes, cardiovascular deaths, and kidney failure .
• An eventual published head-to-head against tirzepatide. As of mid-2026 this has not been announced as a discrete trial; the comparative reading therefore stays inferential.

Bottom line

Retatrutide is the first published triple agonist to clear a Phase 3 efficacy bar. On absolute weight loss magnitude it appears to outperform tirzepatide, with the strong caveat that no head-to-head trial has been published. Side effect profile is broadly class-typical at lower doses, then diverges at higher doses with more GI burden, a clearer heart-rate rise, and a new dysesthesia signal that does not appear on the tirzepatide label.

Tirzepatide has the larger real-world denominator: years of post-marketing data, two FDA-approved indications, a maturing cardiovascular outcomes program (SURPASS-CVOT), and a sleep apnea indication via SURMOUNT-OSA. Retatrutide has the larger short-term weight signal and a fuller registrational program still reading out. The reta-versus-tirz comparison will not be settled by topline announcements or community reports; it will be settled, if at all, by a head-to-head that has not yet been announced and by the rest of the TRIUMPH program. Treat current rankings as provisional.

Anyone reading community experience reports should remember that the gray-market product people are calling 'retatrutide' may or may not be the trial drug. The trial numbers in this piece describe the trial drug at trial-defined doses. The community reports describe what users observed on the product they actually injected. Both data sources are useful; they answer different questions.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article. Concrete decisions about any incretin-class therapy, especially in pregnancy, with cardiovascular or thyroid disease, or alongside insulin or other glucose-lowering drugs, belong with a qualified clinician who can review individual history, comorbidities, and current medications.

For more on how this article was sourced and reviewed, see Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 11 entries (PubMed, ClinicalTrials.gov, DailyMed, FDA, PR Newswire). The TRIUMPH-4 Phase 3 outcome figures come from Eli Lilly topline disclosures (cited to the Lilly press release) and are not yet peer-reviewed or posted to the trial registry. Last reviewed 2026-06-06.

Related tools

• Tirzepatide dose calculator - Run tirzepatide-focused vial draw math.
• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.